Abstract P6-04-11: The foundation one assay influences clinical decision making in metastatic breast cancer
Conclusions:FO utilization is variable based on MBC sub-type and the timing of tissue collection is bimodal. ESR1 mutations were associated with history of prolonged endocrine rx treatment in ER+ IDC and CDH1 mutations were associated with ILC. FO assays frequently influenced clinical treatment decisions but did not result in a high number of pts enrolled on clinical trials. We will update our dataset with additional FO assays and clinicopathologic variables.Citation Format: Harnden KK, Kimmick GG, Marcom PK, Westbrook KE, Blackwell KL. The foundation one assay influences clinical decision making in metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-04-11.
Source: Cancer Research - Category: Cancer & Oncology Authors: Harnden, K., Kimmick, G., Marcom, P., Westbrook, K., Blackwell, K. Tags: Poster Session Abstracts Source Type: research
More News: Academia | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Ductal Carcinoma | Endocrine Therapy | HER2 | Inflammatory Breast Cancer | Lobular Carcinoma | Study